EMKAYNSEEmkay Global Financial Services Limited· Capital MarketsHighNeutral
Announced Fri, 31 Oct, 2025 · 12:48 IST

Q2 FY26: revenue falls sharply, standalone loss, 95 lakh warrants allotted

Revenue DeclinePat NegativeNegative Operating CashflowResults View source PDFExplain this filing

EMKAY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.2%Reaction day
₹308.00
prior close
₹315.40
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+0.6% vs market
Stockbroking & Allied peers, median of 36sector-0.5%+0.8% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.8 pts more than its Stockbroking & Allied peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
-1.2
15m
-1.2
30m
-1.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.2-0.3+0.6-0.5+0.8
Next day
+2.9+0.7+2.2+0.0+2.9
2d
+2.2-0.0+2.3-0.9+3.1
3d
-1.0-1.7+0.8-1.2+0.2
4d
-3.1-1.3-1.8-1.8-1.3
5d
-3.7-1.7-2.0-2.4-1.3
1w
-3.6-1.1-2.6-2.5-1.1
15d
-5.1-4.0-1.1-4.4-0.8
1m
-4.2-3.3-0.9-3.4-0.8
2m
-7.9-5.5-2.3-7.3-0.6
3m
-27.1-12.0-15.1-13.8-13.3
UpDownMarket · Nifty Microcap 250Sector · Stockbroking & Allied peers, median of 36Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 (Sep 2025) consolidated revenue from operations fell 34% to Rs 7,208.58 lakh from Rs 10,856.36 lakh, and profit after tax dropped to Rs 45.95 lakh from Rs 2,590.66 lakh. Standalone posted a Rs 210.64 lakh loss and used Rs 2,610.13 lakh of operating cash in H1. Auditors found no issues. 95 lakh warrants at Rs 239.50 allotted, raising up to Rs 227.52 crore. ICRA reaffirmed BBB positive rating on debentures.

Likely market impact

Weak results may pressure the stock; warrant conversion can dilute equity. Clean auditor review and positive ICRA rating on debentures are reassuring.